Cite
MLA Citation
P Bossuyt et al.. “OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies.” Journal of Crohn's and colitis, vol. 15, n.d., pp. S033–S034. http://access.bl.uk/ark:/81055/vdc_100130765543.0x000011